SLC27A2 antibody - N-terminal region
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC |
---|---|
Primary Accession | O14975 |
Other Accession | NM_003645, NP_003636 |
Reactivity | Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig, Dog |
Predicted | Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig, Dog |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 70kDa |
Gene ID | 11001 |
---|---|
Alias Symbol | ACSVL1, FACVL1, FATP2, HsT17226, VLACS, VLCS, hFACVL1 |
Other Names | Very long-chain acyl-CoA synthetase, VLACS, VLCS, 6.2.1.-, Fatty acid transport protein 2, FATP-2, Fatty-acid-coenzyme A ligase, very long-chain 1, Long-chain-fatty-acid--CoA ligase, 6.2.1.3, Solute carrier family 27 member 2, THCA-CoA ligase, Very long-chain-fatty-acid-CoA ligase, SLC27A2, ACSVL1, FACVL1, FATP2, VLACS |
Format | Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
Reconstitution & Storage | Add 50 ul of distilled water. Final anti-SLC27A2 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles. |
Precautions | SLC27A2 antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | SLC27A2 |
---|---|
Synonyms | ACSVL1, FACVL1, FATP2, VLACS |
Function | Mediates the import of long-chain fatty acids (LCFA) into the cell by facilitating their transport across cell membranes, playing an important role in hepatic fatty acid uptake (PubMed:10198260, PubMed:10749848, PubMed:11980911, PubMed:20530735, PubMed:22022213, PubMed:24269233). Also functions as an acyl-CoA ligase catalyzing the ATP-dependent formation of fatty acyl-CoA using LCFA and very-long- chain fatty acids (VLCFA) as substrates, which prevents fatty acid efflux from cells and might drive more fatty acid uptake (PubMed:10198260, PubMed:10749848, PubMed:11980911, PubMed:20530735, PubMed:22022213, PubMed:24269233). Plays a pivotal role in regulating available LCFA substrates from exogenous sources in tissues undergoing high levels of beta-oxidation or triglyceride synthesis (PubMed:20530735). Can also activate branched-chain fatty acids such as phytanic acid and pristanic acid (PubMed:10198260). May contribute to the synthesis of sphingosine-1-phosphate (PubMed:24269233). Does not activate C24 bile acids, cholate and chenodeoxycholate (PubMed:11980911). In vitro, activates 3-alpha,7-alpha,12-alpha- trihydroxy-5-beta-cholestanate (THCA), the C27 precursor of cholic acid deriving from the de novo synthesis from cholesterol (PubMed:11980911). However, it is not critical for THCA activation and bile synthesis in vivo (PubMed:20530735). |
Cellular Location | Endoplasmic reticulum membrane; Multi-pass membrane protein. Peroxisome membrane; Peripheral membrane protein. Cell membrane; Multi-pass membrane protein. Microsome |
Tissue Location | [Isoform 1]: Expressed in liver, kidney, placenta, intestine, brain, heart, and colon (PubMed:10198260, PubMed:21768100, PubMed:24269233). Predominantly expressed in liver (PubMed:20530735) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
Mihalik,S.J.,(2002)J.Biol.Chem.277(27),24771-24779ReconstitutionandStorage:Forshorttermuse,storeat2-8Cupto1week.Forlongtermstorage,storeat-20Cinsmallaliquotstopreventfreeze-thawcycles.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.